Tracers / [18F]mBPET-1

[18F]mBPET-1

Also written as [18F]mBPET-1; [F-18]mBPET-1
Radionuclide
F-18 t½ 109.77 min
Modality
PET
Production route
—
Stage
—
Syntheses indexed
1
Breast cancerPreclinical only, no clinical indication yet

What it is

Compound class
Benzofuran-based mTOR inhibitor derivative
Target / mechanism
mTOR kinase (mTORC1) inhibitor-based probe PMID 31974638
Clinical application
—
Theranostic pair
—

Regulatory status

FDA
—
EMA (centralised)
—
Other approvals
—
Brand names
—

Clinical use

Typical injected activity
—
Uptake time
—

Reported in the literature. Not a dosing recommendation.

Published syntheses

ModuleCassettePurificationYield %RCP %Precursor / supplierSource
iPHASE FlexLab
iPHASE Technologies
custom manifoldHPLC+SPE40% ± 5%≥99%alkyne precursor 5 / 2-azidoethyl-4-toluenesulfonate31974638
2020 EJNMMI Radiopharm Chem
automated on an iPhase FlexLab synthesis module — The overall radiochemical yield (RCY) of [18F]mBPET-1 was 40% ± 5% (n = 6) after 90 min.

Need this precursor?We can point you to suppliers for [18F]mBPET-1, or handle the enquiry for you.

Get in touch

Quality control Preliminary — inferred from compound class

Ph. Eur. monograph
—
USP monograph
—
AppearancepHRCP HPLCRCP TLCHPLC UVRadionuclidic (HPGe)Half-lifeActivityEndotoxins (LAL)SterilityFilter integrity
How this set was arrived at. base set per Ph. Eur. general monograph 0125 (rule); organic-phase radiosynthesis assumed from isotope/compound class, no synthesis data confirming it -> GC residual solvents (preliminary); conventional nucleophilic 18F-fluorination assumed from isotope/compound class, no synthesis data confirming K222 use -> Kryptofix test (preliminary)

Tests listed by reference only. Monograph texts are copyrighted and are not reproduced here. How these are derived

Setting up quality control?We can help you scope the equipment needed to release [18F]mBPET-1.

Get in touch

Notes

Added from reverse module search (stage 6); 1 article(s) with F-18.